PDF
Erratum | Open Access
Caroline Oudot, Daniel Orbach, Véronique Minard-Colin, Jean Michon, Pierre Mary, Christophe Glorion, Sylvie Helfre, Jean-Louis Habrand, Odile Oberlin, "Erratum to “Desmoid Fibromatosis in Pediatric Patients: Management Based on a Retrospective Analysis of 59 Patients and a Review of the Literature”", Sarcoma, vol. 2013, Article ID 757915, 2 pages, 2013. https://doi.org/10.1155/2013/757915
Erratum to “Desmoid Fibromatosis in Pediatric Patients: Management Based on a Retrospective Analysis of 59 Patients and a Review of the Literature”
We need to update the first and third addresses as shown above. Furthermore, “zero” has been modified and replaced by “—” in Table 3.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| VA: vincristine and dactinomycin; IVA: ifosfamide, vincristine and dactinomycin; VAC: vincristine, dactinomycin, and cyclophosphamide; MTX: methotrexate. : number of patients; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease. *Doxorubicin with vincristine, cisplatin, ifosfamide, cyclophosphamide, or tamoxifen. +Others: VINCAEPI (vincristine, carboplatin, and VM 26), MMT95 protocol (IVA, etoposide, epirubicin, and carboplatin), dactinomycin alone, etoposide-ifosfamide, etoposide alone, and carboplatin. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright
Copyright © 2013 Caroline Oudot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
